<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="917">
  <stage>Registered</stage>
  <submitdate>30/11/2005</submitdate>
  <approvaldate>13/01/2006</approvaldate>
  <actrnumber>ACTRN12606000022561</actrnumber>
  <trial_identification>
    <studytitle>Cancer Shared Care Project Study</studytitle>
    <scientifictitle>Randomised Controlled Trial of a Shared Care Model of Care for patients receiving chemotherapy in a tertiary setting and their General Practitioners, to ascertain benefits to the patient's wellbeing, GP confidence and cost benefit to the tertiary health provider</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Patients receiving chemotherapy for B cell lymphoma or early breast cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Shared Care model - comprised of
1. Patient Held Record
2. GP education
3. Increased GP involvement
4. Shared Care coordinator
The duration of the intervention/control will be for the length of time that the patient is receiving chemotherapy. patients.</interventions>
    <comparator>This is 6 months for the breast cancer patients and 3 months for the Lymphoma </comparator>
    <control>Active</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Measurement of patient mental state.</outcome>
      <timepoint>Measured at commencement of the study, half way through the study (ie 6 weeks for lymphoma patients, 3 months for Breast Cancer patients and at the end of the study ie cessation of chemotherapy)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Number of non treatment visits to tertiary setting.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Cost benefit to the tertiary setting</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3 GP confidence</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Newly diagnosed B cell lymphoma or early breast cancer patients receiving adjuvant chemotherapy.- Patient consent-GP consent.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Inability to understand or complete trial documentation-Patient's GP is already participating in the trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Educational / counselling / training</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Envelopes containing randomisation are generated externally, then opened in front of patient by study coordinator after baseline surveys</concealment>
    <sequence>Sequence generation was done separately within each of the 4 main stata which are rural/metro and lymphoma/breast cancer. Permuted block randomisation used.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>11/11/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>240</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr David Joske (Chief Investigator)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>SCGH Leukaemia Fund</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Principal Investigators: Assoc Prof Alison Ward</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Prof Christobel Saunders</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Prof Jon Emery</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Anna Nowak</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A trial to determine the efficacy of a shared care model of care for patients receiving chemotherapy for lymphoma or breast cancer at Sir Charles Gairdner Hospital, WA.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr David Joske</name>
      <address>Haematology Care Centre
Sir Charles Gairdner Hospital
Hospital Avenue
Nedlands WA 6009</address>
      <phone>+61 8 93467600</phone>
      <fax>+61 8 93467607</fax>
      <email>david.joske@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kate Overheu</name>
      <address>c/- School of Surgery and Pathology
Sir Charles Gairdner Hospital
Hospital Avenue
Nedlands WA 6009</address>
      <phone>+61 8 93464596</phone>
      <fax>+61 8 93462416</fax>
      <email>kate.overheu@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>